Fresenius SE & Co. KGaA, headquartered in Bad Homburg, Germany, was founded in 1912 with a commitment to enhancing the health and quality of life worldwide. The company operates across various segments, primarily focusing on healthcare products and services, including dialysis, hospital management, and clinical nutrition, making it a key player in the global healthcare sector.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| FREGR 0.38% 2026-09-28 EURFresenius SE & Co. KGaA | Germany | 2026-09-28 | 0.375 | 2.56 |
| FREGR 0.75% 2028-01-15 EURFresenius SE & Co. KGaA | Germany | 2028-01-15 | 0.750 | 2.93 |
| FREGR 1.13% 2033-01-28 EURFresenius SE & Co. KGaA | Germany | 2033-01-28 | 1.125 | 3.69 |
| FREGR 1.63% 2027-10-08 EURFresenius SE & Co. KGaA | Germany | 2027-10-08 | 1.625 | 2.96 |
| FREGR 1.88% 2025-05-24 EURFresenius SE & Co. KGaA | Germany | 2025-05-24 | 1.875 | 0.00 |
| FREGR 2.88% 2029-02-15 EURFresenius SE & Co. KGaA | Germany | 2029-02-15 | 2.875 | 2.93 |
| FREGR 2.88% 2030-05-24 EURFresenius SE & Co. KGaA | Germany | 2030-05-24 | 2.875 | 3.24 |
| FREGR 2.96% 2028-10-18 CHFFresenius SE & Co. KGaA | Germany | 2028-10-18 | 2.960 | 0.98 |
| FREGR 4.25% 2026-05-28 EURFresenius SE & Co. KGaA | Germany | 2026-05-28 | 4.250 | 1.99 |
| FREGR 5.00% 2029-11-28 EURFresenius SE & Co. KGaA | Germany | 2029-11-28 | 5.000 | 3.34 |
| FREGR 5.13% 2030-10-05 EURFresenius SE & Co. KGaA | Germany | 2030-10-05 | 5.125 | 3.44 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Fresenius commenced bond issuances in the early 1990s to facilitate expansion and acquisitions, with significant issuances including a €1 billion bond in 2020 to refinance existing debt. As of late 2023, the company’s bond yields typically align with industry standards, offering investors competitive returns. Notably, their bonds often feature callable options, providing flexibility in managing interest costs amid fluctuating market conditions. Recent market activity suggests strong investor interest, reflecting confidence in Fresenius's robust financial strategy and operational stability.